New ETF Book by Larry Connors - Click here to read more
October 6, 2009 (FinancialWire) -- Dr. Eric von Hofe, PhD, president of Antigen Express, Inc., the wholly-owned immunotherapeutics subsidiary of Generex Biotechnology Corp. (NASDAQ: GNBT | Quote | Chart | News | PowerRating) (www.generex.com), is currently featured on the Homeland Security Television Channel, an on-demand television network dedicated to homeland security and global development.
The segment can be viewed online at www.hstvchannel.com and will be available at www.generex.com.
Interviewed by program host and executive producer Dan Verton in an episode titled "2009 Influenza Pandemic Preparedness," Dr. von Hofe discussed the shifting types of flu strains, resulting in new vaccines every season, and distinguished vaccines from antiviral agents and methods that would help cut down on the transmission of the H1N1 virus.
Antigen Express is developing novel immunotherapeutic and prophylactic vaccines for influenza. The company has obtained broad and strong patent coverage for its proprietary platform technologies, which would manufacture modified peptide vaccines by an entirely synthetic process, in contrast with egg-based or cell-culture-based vaccines that require expensive, extensive and labor-intensive manipulation.
"The H1N1 virus has tremendous infectivity in people and was cause for alarm," noted von Hofe. "While H5N1 avian influenza has had a limited impact on humans, the H1N1 virus has shown itself to be highly contagious in humans and might come back."
Dr. von Hofe described best practices for steering clear of the virus and also provided commentary on the new clinical trials approved by the FDA that look at a one-dosage vaccination that would benefit the most vulnerable age demographics, including pregnant women and children six months of age through 24 years of age.
Antigen Express's entirely synthetic vaccine platform reduces cost and increases both the speed and quantity of production. This is of particular benefit in meeting rapidly emerging viral threats such as the potentially pandemic H5N1 avian and H1N1 swine influenzas. Vaccines developed using this platform are already in various stage clinical trials for avian flu, as well as prostate, breast and ovarian cancers.
FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.
Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).
http://www.financialwire.net
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
